Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

Ghayas Issa, Hagop Kantarjian, Musa Yilmaz et al. Nov 03, 2025 pp. 3428-3428 10.1182/blood-2025-3428

Abstract Background and Significance: The menin-KMT2A interaction is a dependency in acute leukemia caused by either rearrangement of the KMT...

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Lijuan Chen, Na Gao, Wei Yang et al. Nov 03, 2025 pp. 908-908 10.1182/blood-2025-908

Abstract Background Myelofibrosis (MF) is characterized by abnormal clonal expansion of hematopoietic stem cells driven by mutations JAK2, C...

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Gabriel Brisou, Emmanuel Bachy, Elodie Gat et al. Nov 03, 2025 pp. 127-127 10.1182/blood-2025-127

Abstract Background Axicabtagene ciloleucel (axi-cel) and Lisocabtagene maraleucel (liso-cel), two anti-CD19 CAR T-cells...

Application of polycythemia vera guidelines in pediatric patient with erythrocytosis: A case series

Marie Kallay, Amanda Claire Jackson Nov 03, 2025 pp. 7323-7323 10.1182/blood-2025-7323

Abstract Background Polycythemia vera (PV) is defined as an increase in red blood cells reflected as an increase in hemo...

Analysis of healthcare utilization costs prior to and after non-myeloablative haploidentical allogeneic stem cell transplantation in adults with sickle cell disease

Ijele Adimora, Bethel Abraham, Robert Brodsky et al. Nov 03, 2025 pp. 2599-2599 10.1182/blood-2025-2599

Abstract Background: Despite robust advances in understanding of sickle cell disease (SCD) pathophysiology, therapeutic options for SCD pati...

Impact of IKZFplus status and ABL1 kinase domain mutations in patients with newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia receiving imatinib and chemotherapy followed by allogeneic SCT within GMALL07/03

Heike Pfeifer, Maher Hanoun, Ahmet Elmaagacli et al. Nov 03, 2025 pp. 3373-3373 10.1182/blood-2025-3373

Abstract Background Several study groups have demonstrated, that alterations in the IKZF1gene at diagnosis and the presence of ABL1 mutations...

A converging crisis: Long-term mortality trends in respiratory failure and anemia inthe United States, 1999–2023

Janta Ukrani, Laiba Sultan, Muhammad Shaheer Bin Faheem et al. Nov 03, 2025 pp. 6456-6456 10.1182/blood-2025-6456

Abstract Background: Respiratory failure and anemia are major contributors to mortality in the United States, particular...

Geographic and temporal trends in sickle cell disease hospitalizations in New York State

Chukwuemeka Iloegbu, Jonathan Odumegwu, Xinyu Wang et al. Nov 03, 2025 pp. 7960-7960 10.1182/blood-2025-7960

Abstract Introduction: Sickle cell disease (SCD) is the most common inherited blood disorder in the United States, disproportionately affect...

Patterns of care in second line management of nodal peripheral T-cell lymphoma from the lymphoma epidemiology of outcomes (LEO) and molecular epidemiology resource (MER) prospective cohort Study

Danielle Wallace, Fnu Aperna, Evelyn Orlando et al. Nov 03, 2025 pp. 3635-3635 10.1182/blood-2025-3635

Abstract Background Nodal peripheral T-cell lymphomas (nPTCLs) are a challenging group of non-Hodgkin lymphomas that frequently recur after o...

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study

Naveen Pemmaraju, Luca Mazzarella, Giovanni Marconi et al. Nov 03, 2025 pp. 5195-5195 10.1182/blood-2025-5195

Abstract Introduction: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy that primarily i...

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

Howard Chang, Staci Williamson, Daniel Chandra et al. Nov 03, 2025 pp. 6085-6085 10.1182/blood-2025-6085

Abstract Background: Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are predominantly diseases of older adults, with media...

Generative AI and knowledge in hematological infectious malignancies: Generating synergies

Gala Cabirta Touzon, Michael Calviño Suárez, Manuel Rodriguez Lopez et al. Nov 03, 2025 pp. 7860-7860 10.1182/blood-2025-7860

Abstract Introduction: Patients with hematological malignancies face a high risk of infectious complications due to immunosuppressive treatm...

Minimal residual disease as a prognostic marker in chronic lymphocytic leukemia: A meta-analysis across chemoimmunotherapy and targeted therapies

Phyo Thazin Myint, Niravkumar Brahmbhatt, Nimisha Halder et al. Nov 03, 2025 pp. 7418-7418 10.1182/blood-2025-7418

Abstract Background Minimal Residual Disease (MRD) assessment is increasingly utilized in the management of Chronic Lymp...

Prognostic impact of cognitive and other impairments in older adults with acute myeloid leukemia (AML) participating in a geriatric assessment-guided treatment selection trial

Vijaya Bhatt, Yue Zhan, Christopher Wichman et al. Nov 03, 2025 pp. 3434-3434 10.1182/blood-2025-3434

Abstract Background: Impairments on geriatric assessment (GA) are common in older adults with AML; hence we designed a trial that used GA gui...

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

Nuria Martínez-Cibrian, Valentin Ortiz-Maldonado, Cristina Blázquez Goñi et al. Nov 03, 2025 pp. 2369-2369 10.1182/blood-2025-2369

Abstract Introduction:Inotuzumab ozogamicin (InO) is a CD22-targeted antibody drug conjugate approved for relapsed/refractory B-cell acute l...

Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma

Pier Luigi Zinzani, Jiri Mayer, Christopher Flowers et al. Nov 03, 2025 pp. 227-227 10.1182/blood-2025-227

Abstract Introduction: While treatment advances have improved outcomes in follicular lymphoma (FL), many patients experience multiple relaps...

Loss of ADAR1-mediated RNA editing disrupts lineage fidelity in human T cell development by inducing interferon response genes

Maria Rivera, Qingfei Jiang, Roman Sasik et al. Nov 03, 2025 pp. 1384-1384 10.1182/blood-2025-1384

Abstract T lymphocytes originate from bone marrow hematopoietic stem cells (HSC) that migrate to the thymus for maturation, selection, and s...

Cytokine score for prognostication of newly diagnosed multiple myeloma

Arwa Bohra, Surendra Dasari, Moritz Binder et al. Nov 03, 2025 pp. 7463-7463 10.1182/blood-2025-7463

Abstract Introduction Multiple myeloma (MM) is clinically heterogeneous, and therapeutic response is profoundly influenced by the complex cy...

Feasibility and efficacy of daratumumab-vcd in transplant-ineligible elderly patients with newly diagnosed multiple myeloma: First results from the multicenter GMMG-dada study

Christof Scheid, Christina Thielen, Sandra Willms et al. Nov 03, 2025 pp. 4050-4050 10.1182/blood-2025-4050

Abstract Background: Daratumumab (Dara) combined with either VRd or Rd is a standard treatment for transplant-ineligible patients with newly...

Innate immune dysregulation in monocytes in sickle cell disease

Sarah Hinderstein, Gemma Vidal-Pedrola, Subhasis Mohanty et al. Nov 03, 2025 pp. 1155-1155 10.1182/blood-2025-1155

Abstract Background : Sickle cell disease (SCD) is the most common genetic hematological disorder affecting ~100,000 people in the United St...

CTA311, a universal anti-CD19 CAR t-cell therapy with improved persistence for patients with CD19+ relapsed/ refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL)

Guangyu Sun, Heng Mei, Anyou Wang et al. Nov 03, 2025 pp. 5920-5920 10.1182/blood-2025-5920

Abstract R/R B-ALL remains difficult to treat with a dismal prognosis, even in the era of autologous CAR-T and targeted therapies. Autologou...

Interpretable deep learning predicts polycythemia vera and identifies novel genomic associations

Tejas Rao, Chepsy Philip, Bani Jolly et al. Nov 03, 2025 pp. 4344-4344 10.1182/blood-2025-4344

Abstract Lowering the haemoglobin cut-off for polycythaemia vera (PV) has markedly increased suspected PV referrals. Polycythemia Vera (PV)...

The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission

Kai Yu, Laura Dillon, Jesse Tettero et al. Nov 03, 2025 pp. 455-455 10.1182/blood-2025-455

Abstract Introduction: Genetic profiling is essential for optimal management of patients with acute myeloid leukemia (AML). Whole genome seq...

Platelet factor 4 (PF4) modulates endothelial cell antimicrobial activity to enhance bacterial clearance and improve sepsis outcomes

Anh Ngo, Weronika Ortmann, Abigail Skidmore et al. Nov 03, 2025 pp. 1322-1322 10.1182/blood-2025-1322

Abstract Introduction: Upon sensing pathogens, platelets (plt) release high concentrations of the positively charged chemokine PF4 from thei...

TCF3::hlf-positive b-ALL: Largest cohort study to date reveals unique molecular landscape and treatment challenges

Xue Chen, Xiaoli Ma, Lili Yuan et al. Nov 03, 2025 pp. 34-34 10.1182/blood-2025-34

Abstract Background: TCF3::HLF-positive B-cell acute lymphoblastic leukemia (B-ALL) represents one of the most aggressive and treatment-refr...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page